You are here: Industry Insights > Serum Institute

News List

Serum Institute of India launches indigenously developed pneumococcal vaccine, ‘PNEUMOSIL’ expresspharma
December 29, 2020
This WHO pre-qualified PCV is specially tailored to the prevailing serotype prevalence of S. pneumoniae in India and other regions of the world.
Covishield can be available in first half of 2021 expresspharma
December 14, 2020
Serum Institute has currently applied with the DCGI for emergency authorization of Covishield in the country.
Serum Institute says in active talks with Indian government around potential COVID-19 vaccines expresspharma
November 30, 2020
Serum Institute of India (SII) is in active discussions with the Indian government on pricing and distribution of potential COVID-19 vaccines, said Adar Poonawalla, Chief Executive SII.
IAVI, Merck KGaA and Serum Institute partner to develop COVID-19 mAbs expresspharma
October 23, 2020
The partnership aims to ensure access to a class of innovative therapies that have, to date, been out of reach in low- and middle-income countries (LMICs).
Serum institute to produce up to additional 100 mn COVID-19 vaccine doses for India and LMIC in 2021 expresspharma
October 09, 2020
The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools Accelerator sees a need for it.
Serum Institute of India: outsourced manufacturing of COVID-19 vaccines europeanpharmaceuticalreview
September 27, 2020
As the COVID-19 pandemic and the search for an effective preventative vaccine continues, the Serum Institute of India has entered into manufacturing agreements with both Novavax and Codagenix to help supply their experimental COVID-19 vaccine candidates.
Serum Institute receives DCGI approval to resume trials of Oxford COVID-19 vaccine expresspharma
September 17, 2020
The DCGI has, however, put certain conditions like taking extra care during screening, providing additional information in informed consent and close monitoring for adverse events during follow-up of the study.
Novavax expands deal with Serum Institute, aims for two billion COVID-19 vaccine doses expresspharma
September 16, 2020
Serum Institute will also manufacture the antigen component of the vaccine, dubbed NVX‑CoV2373.
Novavax and Serum Institute of India Announce Collaboration contractpharma
August 11, 2020
Serum Institute gains exclusive rights to commercialize in India and non-exclusive rights to commercialize in other LMIC countries.
Serum Institute of India gets DCGI nod for phase 2 and 3 human trials of Oxford vaccine candidate expresspharma
August 04, 2020
As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals.

Previous page 1 2 3 Next page